Skip to main content
Premium Trial:

Request an Annual Quote

US DoD Taps CombiMatrix to Develop Point-of-Care Testing System

NEW YORK (GenomeWeb News) – The US Department of Defense has awarded CombiMatrix a fifteen-month contract worth more than $900,000 to develop a hand-held detection system for military use, the company said today.
 
The contract follows a one-year, $2.2 million agreement the company signed last July with the DoD to develop microarrays to detect pathogens and toxins, and two DoD awards that it won in 2006.
 
CombiMatrix said today that the instrument it will develop under the new contract will be the “size of a deck of playing cards,” which will allow it to be used in the field of operations in military applications.
 
The company said it expects the system will also be of interest in the civilian market for point-of-care testing “as well as other applications and markets that are currently not accessible due to instrument size, complexity and/or expense.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.